In critical care, tackling organ failures in real-time with an integrated and personalized approach is the priority road to effectively face diseases such as: sepsis, renal failure, respiratory and multi-organ failure in general, and all diseases with mortality rates still above 50%. AMPLYA™ is a multitherapeutic system for critical care. Integration of multiple extracorporeal treatments – from the more conventional to adsorption treatments – widens the therapeutic opportunities in case of organ failure.
CPFA
CPFA® is an extracorporeal therapy that Bellco developed and patented for the treatment of patients with multi-organ failure (MOF) or sepsis. At present, sepsis is considered the result of a failed equilibrium between pro- and anti-inflammatory mediators. CPFA®, the therapy used for mediator removal, plays a unique and fundamental role. The technique consists of using a sorbent composed of a synthetic resin which acts directly on the plasma separated from the whole blood. CPFA®allows effective reduction of inflammation factors, notable improvement in the immunocompetences, a marked rise in the survival rate as well as an improvement in hemodynamics and leucocytic response.
Abylcap
Abylcap® removes CO2 quickly, easily and effectively with utmost safety while at the same time optizing mechanical ventilation and protecting the patient’s lungs. Bellco proposes this new method, integrated with the Lynda system, to treat patients suffering from ALI (Acute Lung Injury) and ARDS (Acute Respiratory Distress Syndrome) triggered by other disease such as sepsis, MOF (Multi Organo Failure), COPD (Chronic Obstructive Pulmonary Disease) and multi-trauma.
Abylcap® funcions accoridng to a simple and safe mechanism: the blood aspirated from the patient is directed to the oxygenator, which progressively removes CO2 by means of a special phosphorylcholine-coated membrane, bringing levels down to optimal values.
Four consecutive days of treatment guaranted: the system can conduct four consecutive days of treament thanks to properties of the membrane that maintain its performance.
Renal Replacement Therapy
AMPLYA™ offers the possibility of performing continuous or intermittent renal failure treatments through the use of highly biocompatible blood filters or haemodialysers of different surface areas. Based on the use of these types of filters, treatments such as isolated ultrafiltration, haemofiltration, haemodialysis and haemodiafiltration can be performed.
Renal intermittent Therapies
- IHF-HVHF – intermittent hemo filtration – High Volume Hemofiltration
- IHD-SLED – intermittent hemodialysis – Slow Low Efficiency Dialysis
- IHDF – intermittent hemodia filtration
CRRT (Continuous Renal Replacement Therapy)
- SCUF – slow continuous ultrafiltration
- CVVH – continuous veno-venous hemofiltration
- CVVHD – continuous veno-venous hemodialysis
- CVVHDF – continuous veno-venous hemodiafiltration
WhatsApp us